FDA Grants Mirvetuximab Full Approval for Ovarian Cancer
Mirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor–alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-grants-mirvetuximab-full-approval-ovarian-cancer-2024a10005m0?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-grants-mirvetuximab-full-approval-ovarian-cancer-2024a10005m0?src=rss
Comments
Post a Comment